EAM Investors LLC cut its holdings in Exact Sciences Corporation (NASDAQ:EXAS) by 34.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 63,983 shares of the medical research company’s stock after selling 33,967 shares during the period. EAM Investors LLC owned 0.05% of Exact Sciences Corporation worth $3,015,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Advisor Group Inc. raised its position in Exact Sciences Corporation by 0.8% in the second quarter. Advisor Group Inc. now owns 7,866 shares of the medical research company’s stock worth $270,000 after acquiring an additional 65 shares during the period. Ameritas Investment Partners Inc. raised its position in Exact Sciences Corporation by 5.6% in the second quarter. Ameritas Investment Partners Inc. now owns 9,640 shares of the medical research company’s stock worth $341,000 after acquiring an additional 511 shares during the period. Northwestern Mutual Wealth Management Co. raised its position in Exact Sciences Corporation by 17.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 4,072 shares of the medical research company’s stock worth $144,000 after acquiring an additional 600 shares during the period. Lincoln National Corp raised its position in Exact Sciences Corporation by 7.8% in the second quarter. Lincoln National Corp now owns 10,104 shares of the medical research company’s stock worth $357,000 after acquiring an additional 728 shares during the period. Finally, Johnson Financial Group Inc. raised its position in Exact Sciences Corporation by 25.9% in the second quarter. Johnson Financial Group Inc. now owns 4,862 shares of the medical research company’s stock worth $172,000 after acquiring an additional 1,000 shares during the period. Institutional investors and hedge funds own 86.04% of the company’s stock.

Several research analysts have weighed in on EXAS shares. Vetr upgraded shares of Exact Sciences Corporation from a “sell” rating to a “hold” rating and set a $36.55 price target on the stock in a research report on Tuesday, July 25th. Lake Street Capital increased their price target on shares of Exact Sciences Corporation from $30.00 to $41.00 and gave the stock a “hold” rating in a research report on Wednesday, July 26th. Craig Hallum reiterated a “buy” rating and issued a $46.00 price target (up from $41.00) on shares of Exact Sciences Corporation in a research report on Wednesday, July 26th. Roth Capital increased their price target on shares of Exact Sciences Corporation from $40.00 to $46.00 and gave the stock a “buy” rating in a research report on Wednesday, July 26th. Finally, Bank of America Corporation reiterated a “buy” rating on shares of Exact Sciences Corporation in a research report on Wednesday, July 26th. Eight analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. Exact Sciences Corporation has a consensus rating of “Buy” and an average target price of $49.98.

COPYRIGHT VIOLATION WARNING: This piece was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/11/21/eam-investors-llc-sells-33967-shares-of-exact-sciences-corporation-exas.html.

Exact Sciences Corporation (NASDAQ:EXAS) traded up $0.48 on Tuesday, reaching $59.34. 402,862 shares of the company traded hands, compared to its average volume of 2,526,074. Exact Sciences Corporation has a 52 week low of $13.05 and a 52 week high of $63.60. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.34 and a quick ratio of 9.98.

Exact Sciences Corporation (NASDAQ:EXAS) last posted its earnings results on Monday, October 30th. The medical research company reported ($0.23) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.30) by $0.07. The company had revenue of $72.60 million during the quarter, compared to analysts’ expectations of $65.03 million. Exact Sciences Corporation had a negative net margin of 60.71% and a negative return on equity of 30.32%. Exact Sciences Corporation’s quarterly revenue was up 158.4% on a year-over-year basis. During the same period last year, the company posted ($0.36) earnings per share. research analysts predict that Exact Sciences Corporation will post -1.12 EPS for the current year.

In other Exact Sciences Corporation news, insider Graham Peter Lidgard sold 75,683 shares of Exact Sciences Corporation stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $40.81, for a total value of $3,088,623.23. Following the completion of the transaction, the insider now directly owns 308,377 shares of the company’s stock, valued at approximately $12,584,865.37. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Kevin T. Conroy sold 137,805 shares of Exact Sciences Corporation stock in a transaction on Thursday, November 9th. The stock was sold at an average price of $59.14, for a total transaction of $8,149,787.70. Following the completion of the transaction, the chief executive officer now directly owns 967,867 shares of the company’s stock, valued at $57,239,654.38. The disclosure for this sale can be found here. Insiders have sold 415,178 shares of company stock valued at $20,785,358 over the last ninety days. 4.00% of the stock is currently owned by corporate insiders.

About Exact Sciences Corporation

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exact Sciences Corporation (NASDAQ:EXAS).

Institutional Ownership by Quarter for Exact Sciences Corporation (NASDAQ:EXAS)

Receive News & Stock Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related stocks with our FREE daily email newsletter.